Stockscreener 앱 받기
2.65
2.71%
0.07
시간 외 거래:
2.72
0.07
+2.64%
전일 마감가:
$2.58
열려 있는:
$2.54
하루 거래량:
72,480
Relative Volume:
0.03
시가총액:
$5.81M
수익:
-
순이익/손실:
$-4.74M
주가수익비율:
-3.5333
EPS:
-0.75
순현금흐름:
$-3.46M
1주 성능:
+10.42%
1개월 성능:
+6.00%
6개월 성능:
-19.37%
1년 성능:
-53.25%
1일 변동 폭
$2.54
$2.74
1주일 범위
$2.03
$2.74
52주 변동 폭
$1.965
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
명칭
Lipella Pharmaceuticals Inc
전화
412-901-0315
주소
400 N LEXINGTON ST, PITTSBURGH
LIPO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.65 | 5.81M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc 주식(LIPO)의 최신 뉴스
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com India
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World
FDA approves Lipella's oral treatment access program - MSN
Lipella Pharmaceuticals modifies agreement with Spartan Capital By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals modifies agreement with Spartan Capital - Investing.com
With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus - News & Insights
Analyzing Lipella Pharmaceuticals (NASDAQ:LIPO) and IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310 - TipRanks
3 Penny Stocks to Watch Now, 2/13/25 - TipRanks
Lipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus Treatment - Defense World
Biotech Rips On Topline Analysis - The Globe and Mail
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - AOL.com
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment - Marketscreener.com
Stock market news: Firefly Neuroscience +214.56%, Dominari Holdings +37.66% among top gainers during midday trading - Business Upturn
Stock market today: Firefly Neuroscience +60.32%, Dominari Holdings +36.36% among top gainers in early trading - Business Upturn
Lipella Pharmaceuticals Inc (LIPO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):